Agreement Expands Global Availability of Primary Cells

A private label partnership for the manufacture and global commercialisation of an extensive range of hematopoietic primary cells has been agreed by Lonza and US company AllCells.

The addition of the entire AllCells research portfolio of products, which has expanded Lonza’s branded cell lines is available to scientists on a global scale to further their research across an array of applications, including drug discovery, toxicity testing, cell therapy and personalized medicine. 

Hematopoietic primary cells play a vital role in advancing in vitro research as they closely reflect in vivo morphology, metabolism and growth characteristics. However, obtaining those cells requires researchers to find a variety of donors and perform a series of tedious cell isolations.

“With this partnership, we aim to enable straightforward access to a wealth of viable, ready-to-use hematopoietic cells, such as mobilised peripheral blood progenitor cells,” said Mary Riley, Director of Discovery Solutions at Lonza. “All researchers will need to do is thaw and culture, while also being able to take advantage of Lonza’s strong after-sales technical support.”

Don Klabunde, CEO at AllCells, added: “By leveraging our customisation expertise, speed and flexibility to manufacture hematopoietic cells of superior viability and quality and with Lonza's extensive reach, we will improve the availability of highly purified cells from different tissue sources to enhance a variety of research needs.”